Developmental screening of full-term infants at 16 to 18 months of age after in-utero exposure to maternal SARS-CoV-2 infection

doi:10.21203/rs.3.rs-2014302/v1

Full-term infants born to mothers with SARS-CoV-2 infection may be at increased risk for neurodevelopmental delays at 16 to 18 months of life. Infants born to the mothers with mild symptoms had no differences in outcomes during developmental screening than those born to asymptomatic mothers with SARS-CoV-2.

COVID-19

Coronavirus disease 2019 (COVID-19) pandemic caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has resulted in significant morbidity and mortality throughout the world. Pregnant mothers with SARS-CoV-2 infection are more likely to deliver prematurely, require respiratory support and intensive care unit (ICU) admission (1). Additionally, infants born to mothers with COVID-19 are more likely to have morbidities associated with being born premature and require neonatal intensive care unit (NICU) admission. However, the impact of in-utero exposure to maternal SARS-CoV-2 infection on long-term infant neurodevelopment outcomes is currently unknown.

Studies have shown that the vertical transmission of SARS-CoV-2 occurs rarely. Nevertheless, activation of the maternal immune response could impact the long-term outcomes in children as observed after other maternal viral infections. While some intra-uterine viral infections, such as ToRCH (Toxoplasma, rubella, cytomegalovirus, and herpes), human immunodeficiency virus and Zika, can cause direct effects on neurodevelopmental outcomes of children through invasion of brain tissues (2-4), other viruses, such as influenza, may cause adverse neurodevelopmental effects via maternal and placental immune activation (5, 6). Recent flu epidemics in the 21^st century have indicated that maternal influenza infection might have long-term effects on children even after infancy, necessitating the need for life course studies (7, 8). Activation of maternal immune response, increased inflammation and altered cytokines expression have been postulated as some of the mechanisms causing long-term effects among infants (9-13). Prematurity is a known risk factor for neurodevelopmental delays necessitating closer follow-up, but those who are born at full-term after maternal SARS-CoV-2 need to be carefully evaluated to understand if they could be at increased risk as well. Additionally, the differential impact of symptomatic or asymptomatic maternal SARS-CoV-2 infection status as well as maternal illness severity remains unknown. Our institution was at the epicenter of the COVID-19 pandemic in March 2020 in New York City. We followed full-term infants born to mothers with confirmed SARS-CoV-2 at our center and report preliminary findings of developmental screening performed at 16 to 18 months of age.

This was an institutional review board approved, prospective descriptive cohort study of full-term infants (≥ 37 weeks’ gestation age) born to mothers with confirmed SARS-CoV-2 infection. All mothers were tested by real-time reverse transcriptase polymerase chain reaction of nasopharyngeal swabs, documented anytime during pregnancy on outpatient or inpatient visits between March 1, 2020 and July 31, 2020 based on maternal symptoms or universal screening of all those admitted to labor and delivery unit (started on March 30, 2020), from a large academic tertiary care center in New York City (1, 14). Infants born premature (< 37 weeks gestational age) or those with known major congenital/genetic diagnoses were excluded.

A standardized validated tool, the Ages and Stages Questionnaires^®-Third Edition (ASQ^®-3), was administered by trained personnel via telephone for screening of neurodevelopment in five domains (communication, fine and gross motor, problem solving, and personal social skills) at 16 to 18 months age (15). Each domain was individually scored into three categories, as defined by the ASQ^®-3 technical manual: 1) above the cutoff (corresponding to normal development), 2) close to the cutoff (corresponding to between 1 and 2 standard deviations below the mean), and 3) below the cutoff (corresponding to ≥ 2 standard deviations below the mean) (16). Data for maternal-infant dyads were obtained from electronic charts. Mean, median and percentages were used for descriptive data. Categorical variables between symptomatic (14) and asymptomatic mothers were compared using Fisher’s exact test on IBM-SPSS® 24.0. A P-value < .05 was considered significant.

Seventy-eight families were approached, of whom 51 (65%) provided consent and completed the ASQ^®-3. Mean (standard deviation [SD]) maternal age was 30.5 (SD 6.1) years and infant mean gestation age at birth was 39.4 (SD 1.2) weeks. Mean age of subjects at ASQ^®-3 screening was 17.2 (SD 1) months. Other maternal and neonatal demographic information is described in Table 1 (online). 12 subjects (24%) were below cutoff in at least one domain. 15 (29%) subjects were close to the cutoff in at least one domain. Cumulatively, 27 subjects (53%) were either below or close to the cutoff in at least one developmental domain. Of five domains, communication, fine motor, and problem-solving were most affected as either below or close to the cutoff, in 29%, 31% and 24% subjects respectively (Fig. 1).

Table 1

Baseline maternal and neonatal demographics (*: data expressed in mean ± standard deviation, ^#one baby was admitted to the NICU for brief observation only. Abbreviations: IQR- interquartile range, NICU- neonatal intensive care unit, LGA- large for gestation age, AGA- appropriate for gestation age, SGA- small for gestation age, n- number of subjects)
Baseline demographics	n = 51
Gestational age, weeks^*	39.4 ± 1.2
Maternal age, years^*	30.5 ± 6.1
Cesarean delivery, %	25
Female, %	53
Apgar score, median - 1 minute - 5 minute	9 (IQR 8–9) 9 (IQR 9–9)
Birth weight, grams*	3343 ± 379
NICU Admission^#	1 (2%)
AGA/LGA/SGA	49/1/1 (96%/2%/2%)
Age at ASQ^®*-3screening, months**	17.2 ± 1
Public Insurance, %	47
COVID Symptoms of those symptomatic at time of delivery (cough / fever / loss of smell)	60% / 50% / 20%

Twenty-one (41%) mothers were symptomatic, of whom ten (20%) were symptomatic ≤ 14 days and eleven (22%) were symptomatic > 14 days before delivery. None of the mothers required respiratory support or intensive care in this cohort. The most common maternal symptoms included cough, fever, and myalgia. None of the mothers were diagnosed with chorioamnionitis in this cohort. There were no significant differences between subjects who were either below, and/or close to the cutoff born to asymptomatic and symptomatic mothers regardless of timing of symptoms during pregnancy (Table 2).

Table 2

Comparison of neurodevelopmental screening between children born to asymptomatic or symptomatic mothers with SARS-CoV-2 infection. Symptomatic mothers are further subdivided into those who had symptoms ≤ 14 days or any time before delivery (n = number of subjects).
	All patients, n = 51	Asymptomatic (reference group), n = 30	Symptomatic ≤ 14 days, n = 10	P-value	Symptomatic anytime during third trimester, n = 21	P-value
Below cutoff, n (%)	12 (24)	5 (17)	1 (10)	.99	7 (33)	.20
Only close to cutoff, n (%)	15 (29)	8 (27)	5 (50)	.24	7 (33)	.76
Either below or close to cutoff, n (%)	27 (53)	13 (43)	6 (60)	.47	14 (67)	.15

In this study, we observed about one in four infants born at full-term to mothers with SARS-CoV-2 during pregnancy were at risk for developmental delays determined by having at least one developmental domain below cut-off on ASQ^®-3 screening at 16 to 18 months of age. Additionally, we observed no differences in outcomes between infants born to asymptomatic and mildly symptomatic mothers with SARS-CoV-2. These results highlight the urgent need for follow-up studies of infants born to mothers with SARS-CoV-2.

The literature on ASQ^®-3 developmental screening of low-risk full-term infants show a positive screen in 12.6–13.6% children in at least one developmental domain (15, 17). In our study cohort, we observed that 24% of subjects were ‘below cutoff’ in at least one developmental domain and an additional 29% were ‘close to the cutoff’ in at least one domain, significantly more than what would be expected for a medically low-risk cohort of full-term infants without any genetic or congenital anomalies. These results are similar to preliminary evidence from other emerging epidemiological studies suggesting association of maternal SARS-CoV-2 with neurodevelopmental sequelae in some offspring (18). Edlow et al. observed greater rate of neurodevelopmental diagnoses in 222 infants born to SARS-CoV-2 positive mothers at 12 months of age after adjusting for multiple confounding factors including prematurity (adjusted OR 1.86, CI 1.03–3.36, P = .04), particularly during third-trimester maternal infection (18). However, their study relied on International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) diagnostic codes, which may lead to misclassification and lacks the sensitivity of a prospective neurodevelopmental screening such as in our study. Shuffrey and colleagues concluded in their study that birth during the pandemic and not in-utero exposure to maternal SARS-CoV-2 infection was associated with differences in neurodevelopment at 6 months of age (19). Both these studies had limited duration of follow-up until maximum one year of age, which may not yet identify risk in subjects on developmental screening assessment when compared to 16 to 18 months of age as performed in our study.

Similar to prior studies, we observed increased concerns in communication, fine motor, and problem-solving neurodevelopmental domains (19–21). Other than possibility of these findings being related to the effects on fetus from maternal immune response after SARS-CoV-2 infection, it could also possibly reflect societal and behavioral changes or stressors that occurred during COVID-19 pandemic resulting in these preliminary findings (21–24). Therefore, it would be important to differentiate impact of maternal immune activation to those from pandemic related effects on infant neurodevelopment in future studies.

In this cohort of mothers with asymptomatic or mild symptomatic infection, there was no difference in outcomes of their children due to symptomatic maternal status. Most symptomatic mothers with SARS-CoV-2 requiring respiratory support or intensive care delivered prematurely and therefore excluded from this study. However, national data suggests that vast majority of mothers with SARS-CoV-2 deliver at full-term and have asymptomatic or mild infection (25). Therefore, it is important to screen these infants in studies like ours from an epidemiological and public health perspective.

Our study has limitations. It has a small sample size from a single center. There is a possibility of ascertainment bias due to likelihood that parents who had concerns for development of their child were more likely to participate in the study, although standardized information was presented to parents while obtaining consent. There is absence of ideal comparable cohort of subjects who were born to mothers with negative SARS-CoV-2 testing during similar timeframe of pandemic as opposed to standardized ASQ^®-3 historical averages. The added stressors during the pandemic of inconsistent childcare, food insecurity, job and housing losses could confound the risk of having further developmental delays (21–24). Finally, while ASQ^®-3 is a validated questionnaire that can be administered virtually, however, it would be important to have follow up with in-person assessments to further identify degree of developmental delays.

Despite these limitations, it is clear that further research is warranted to study long-term effects on infants born to mothers with SARS-CoV-2 during pregnancy. Findings of this study add to the evidence of possible risk for neurodevelopmental delays in infants due to maternal COVID infection. Studies which follow these children will be important to document longer term neurodevelopmental problems in full-term infants (26, 27). While infants of mothers more severely affected and delivered prematurely are likely to be at increased risk for adverse neurodevelopmental outcomes, this study shows that the monitoring of infants whose mothers were asymptomatic or mildly symptomatic with SARS-CoV-2 infection and progressed to full-term for delivery is warranted as well.

In conclusion, we observed increased risk of neurodevelopmental delays during screening of infants born at full term to mothers with SARS-CoV-2 at 16 to 18 months of age. Additionally, we observed no difference in outcomes between infants born to asymptomatic and mildly symptomatic mothers with SARS-CoV-2. These results highlight the urgent need for follow up studies of infants born to mothers with SARS-CoV-2.

Conflict of Interest Disclosures (includes financial disclosures): None

Funding/Support: No funding was secured for this study.

Role of Funder/Sponsor: N/A

Verma S, Bradshaw C, Auyeung NSF, Lumba R, Farkas JS, Sweeney NB, et al. Outcomes of Maternal-Newborn Dyads After Maternal SARS-CoV-2. Pediatrics. 2020;146(4).
Bartlett AW, McMullan B, Rawlinson WD, Palasanthiran P. Hearing and neurodevelopmental outcomes for children with asymptomatic congenital cytomegalovirus infection: A systematic review. Rev Med Virol. 2017.
Ferguson G, Jelsma J. The prevalence of motor delay among HIV infected children living in Cape Town, South Africa. Int J Rehabil Res. 2009;32(2):108–14.
Hutchinson KM, Sandall SR. Congenital TORCH infections in infants and young children: Neurodevelopmental sequelae and implications for intervention. Topics in Early Childhood Special Education. 1995;15 (1):65–82.
Almond D, Mazumder B. The 1918 Influenza Pandemic and Subsequent Health Outcomes: An Analysis of SIPP Data. Am Econ Rev. 2005;95(2):258–62.
Helgertz J, Bengtsson T. The Long-Lasting Influenza: The Impact of Fetal Stress During the 1918 Influenza Pandemic on Socioeconomic Attainment and Health in Sweden, 1968–2012. Demography. 2019;56(4):1389–425.
McCarthy J, Liu D, Kaskel F. The Need for Life-Course Study of Children Born to Mothers With Prior COVID-19 Infection. JAMA Pediatr. 2021;175(11):1097–8.
Song JY, Park KV, Han SW, Choi MJ, Noh JY, Cheong HJ, et al. Paradoxical long-term impact of maternal influenza infection on neonates and infants. BMC Infect Dis. 2020;20(1):502.
Adams Waldorf KM, McAdams RM. Influence of infection during pregnancy on fetal development. Reproduction. 2013;146(5):R151-62.
Cordeiro CN, Tsimis M, Burd I. Infections and Brain Development. Obstet Gynecol Surv. 2015;70(10):644–55.
Meyer U, Yee BK, Feldon J. The neurodevelopmental impact of prenatal infections at different times of pregnancy: the earlier the worse? Neuroscientist. 2007;13(3):241–56.
Shook LL, Sullivan EL, Lo JO, Perlis RH, Edlow AG. COVID-19 in pregnancy: implications for fetal brain development. Trends Mol Med. 2022;28(4):319–30.
Urakubo A, Jarskog LF, Lieberman JA, Gilmore JH. Prenatal exposure to maternal infection alters cytokine expression in the placenta, amniotic fluid, and fetal brain. Schizophr Res. 2001;47(1):27–36.
Centers for Disease Control and Prevention. Symptoms of Coronavirus Disease 2019 2020 [Available from: https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html.
The Ages & Stages Questionnaires®, Third Edition (ASQ®-3) 2022 [Available from: https://agesandstages.com/products-pricing/asq3/.
ASQ-3 Technical Report [Available from: https://agesandstages.com/wp-content/uploads/2017/05/ASQ-3-Technical-Appendix_web.pdf.
Agarwal PK, Xie H, Sathyapalan Rema AS, Rajadurai VS, Lim SB, Meaney M, et al. Evaluation of the Ages and Stages Questionnaire (ASQ 3) as a developmental screener at 9, 18, and 24 months. Early Hum Dev. 2020;147:105081.
Edlow AG, Castro VM, Shook LL, Kaimal AJ, Perlis RH. Neurodevelopmental Outcomes at 1 Year in Infants of Mothers Who Tested Positive for SARS-CoV-2 During Pregnancy. JAMA Netw Open. 2022;5(6):e2215787.
Shuffrey LC, Firestein MR, Kyle MH, Fields A, Alcantara C, Amso D, et al. Association of Birth During the COVID-19 Pandemic With Neurodevelopmental Status at 6 Months in Infants With and Without In Utero Exposure to Maternal SARS-CoV-2 Infection. JAMA Pediatr. 2022:e215563.
Edlow AG, Li JZ, Collier AY, Atyeo C, James KE, Boatin AA, et al. Assessment of Maternal and Neonatal SARS-CoV-2 Viral Load, Transplacental Antibody Transfer, and Placental Pathology in Pregnancies During the COVID-19 Pandemic. JAMA Netw Open. 2020;3(12):e2030455.
Huang P, Zhou F, Guo Y, Yuan S, Lin S, Lu J, et al. Association Between the COVID-19 Pandemic and Infant Neurodevelopment: A Comparison Before and During COVID-19. Front Pediatr. 2021;9:662165.
Kendrick K, Isaac M. Overview of behavioural and psychological consequences of COVID 19. Curr Opin Psychiatry. 2021;34(5):477–84.
King LS, Feddoes DE, Kirshenbaum JS, Humphreys KL, Gotlib IH. Pregnancy during the pandemic: the impact of COVID-19-related stress on risk for prenatal depression. Psychol Med. 2021:1–11.
Robillard R, Saad M, Edwards J, Solomonova E, Pennestri MH, Daros A, et al. Social, financial and psychological stress during an emerging pandemic: observations from a population survey in the acute phase of COVID-19. BMJ Open. 2020;10(12):e043805.
Centers for Disease Control and Prevention. Pregnant and Recently Pregnant People 2022 [Available from: https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/pregnant-people.html.
DeSisto CL, Wallace B, Simeone RM, Polen K, Ko JY, Meaney-Delman D, et al. Risk for Stillbirth Among Women With and Without COVID-19 at Delivery Hospitalization - United States, March 2020-September 2021. MMWR Morb Mortal Wkly Rep. 2021;70(47):1640–5.
Schwartz DA, Avvad-Portari E, Babal P, Baldewijns M, Blomberg M, Bouachba A, et al. Placental Tissue Destruction and Insufficiency From COVID-19 Causes Stillbirth and Neonatal Death From Hypoxic-Ischemic Injury. Arch Pathol Lab Med. 2022;146(6):660–76.

There is NO conflict of interest to disclose.

Developmental screening of full-term infants at 16 to 18 months of age after in-utero exposure to maternal SARS-CoV-2 infection

Status:

Journal Publication

Version 1

Abstract

Figures

Introduction

Methods

Results

Discussion

Declarations

References

Additional Declarations

Status:

Journal Publication

Version 1